Ligand Pharmaceuticals (LGND) Non-Current Assets (2010 - 2026)

Ligand Pharmaceuticals has disclosed Non-Current Assets across 17 years of filings, most recently posting $666.7 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $666.7 million, up 11.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 billion (up 12.79% YoY), and the FY2025 annual result was $728.4 million, up 19.36% from the prior year.
• Non-Current Assets came in at $666.7 million for Q1 2026 at Ligand Pharmaceuticals, down from $728.4 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $832.5 million in Q2 2022 to a low of $481.4 million in Q2 2023.
• The 5-year median for Non-Current Assets is $596.1 million (2025), against an average of $628.5 million.
• Across the five-year window, Non-Current Assets tumbled 42.18% in 2023 and advanced 25.28% in 2024, its largest moves.
• Ligand Pharmaceuticals' Non-Current Assets stood at $499.1 million in 2022, then grew by 10.16% to $549.8 million in 2023, then grew by 10.99% to $610.2 million in 2024, then climbed by 19.36% to $728.4 million in 2025, then retreated by 8.47% to $666.7 million in 2026.
• The last three Non-Current Assets figures came in at $666.7 million (Q1 2026), $728.4 million (Q4 2025), and $722.9 million (Q3 2025), per Business Quant data.